🟢 Precigen is trading 13.3% up in pre-market ahead of its November 4 third-quarter results

Precigen is trading at $5.95 (+13.31%) in pre-market ahead of its November 4 report.

• Third-quarter results and business updates are scheduled after the market closes November 4; results were unavailable at 4:54 a.m. ET.
• The S&P 500, Nasdaq and Dow are up 0.72%, 0.65% and 1.09%, respectively; broader gains may contribute but do not establish the cause.
• Reports cite concerns after Inovio received FDA approval for Voceryq, but do not link that news to Precigen’s move.